Tom van Meerten
Overview
Explore the profile of Tom van Meerten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Spanjaart A, Pennings E, Mutsaers P, van Dorp S, Jak M, van Doesum J, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686611
The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates...
12.
de Boer J, Pennings E, Kleinjan A, van Doesum J, Spanjaart A, Mutsaers P, et al.
Blood Adv
. 2023 Aug;
7(21):6710-6716.
PMID: 37639324
No abstract available.
13.
Hofsink Q, Haggenburg S, Lissenberg-Witte B, Broers A, van Doesum J, van Binnendijk R, et al.
EClinicalMedicine
. 2023 Jun;
61:102040.
PMID: 37337616
Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this...
14.
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, et al.
N Engl J Med
. 2023 Jun;
389(2):148-157.
PMID: 37272527
Background: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19...
15.
van Doesum J, Salmanton-Garcia J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al.
Blood Adv
. 2023 Apr;
7(11):2645-2655.
PMID: 37058479
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown...
16.
Westin J, Locke F, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1894-1905.
PMID: 36999993
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of...
17.
Keijzer K, Niezink A, de Boer J, van Doesum J, Noordzij W, van Meerten T, et al.
Comput Struct Biotechnol J
. 2023 Feb;
21:1102-1114.
PMID: 36789266
In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be...
18.
Spanjaart A, Pennings E, Kos M, Mutsaers P, Lugtenburg P, van Meerten T, et al.
JCO Oncol Pract
. 2022 Dec;
19(3):e407-e416.
PMID: 36508702
Purpose: Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell-mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting,...
19.
Langendonk M, Smit N, Plattel W, Diepstra A, van Meerten T, Visser L
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430230
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities...
20.
Tienstra M, de Boer J, van Doesum J, van Meerten T, van Dijk P
Diabet Med
. 2022 Oct;
40(2):e14969.
PMID: 36209376
No abstract available.